|
Match
|
Document |
Document Title |
|
|
US20150338393 |
METHODS FOR TREATING NEURAL CELL SWELLING
A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different... |
|
|
US20110262543 |
PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES
Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared. |
|
|
US20110064808 |
EXTENDED RELEASE FORMULATION OF LEVETIRACETAM
The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core... |
|
|
US20110064807 |
EXTENDED RELEASE FORMULATION OF LEVETIRACETAM
An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core... |
|
|
US20100035854 |
DRY POWDER FORMULATIONS
A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further... |
|
|
US20090312390 |
INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA
The use of inhibitors of GSK-3 useful for treating glaucoma is disclosed. |
|
|
US20080114052 |
CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis,... |
|
|
US20070274951 |
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor but... |
|
|
US20060154934 |
Combinations comprising antimuscarinic agents and PDE4 inhibitors
Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)
-1-azoniabicyclo[2.2.2]octane,... |
|
|
US20050107445 |
Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader... |
|
|
US20120065174 |
COMPOSITIONS OF GLYCOPYRRONIUM SALT FOR INHALATION
A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an... |
|
|
US20110251171 |
HETEROCYCLIC COMPOUNDS AND METHODS OF USE
Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are... |
|
|
US20110132357 |
COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension... |
|
|
US20100273724 |
PEGYLATED ION CHANNEL MODULATING COMPOUNDS
This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also... |
|
|
US20050171187 |
2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the... |
|
|
US20050037984 |
Methods for Alzheimer's Disease treatment and cognitive enhancement
The present invention relates to compositions and methods to modulate α-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in... |
|
|
US20170112763 |
METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS
Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided. |
|
|
US20160081924 |
PHARMACEUTICAL COMPOSITIONS
This invention provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for delivery to the lung by inhalation. This invention also... |
|
|
US20150059746 |
METHOD AND APPARATUS
A method is disclosed for making a pharmaceutical composition for pulmonary administration, the method comprising a step in which an inhalable pharmaceutically active material is acoustically... |
|
|
US20140255491 |
Method and System For the Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Anticholinergic Administrations
Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided. |
|
|
US20110027359 |
Novel Pharmaceutical Compositions Comprising Levetiracetam
The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation. |
|
|
US20090215734 |
METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS
Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided. |
|
|
US20080009498 |
Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use
The invention provides novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous... |
|
|
US20050065205 |
Methods for Alzheimer's disease treatment and cognitive enhance
The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability;... |
|
|
US20160374987 |
TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION
Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The... |
|
|
US20150320722 |
FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS
Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft... |
|
|
US20150141481 |
Treatment of Chronic Obstructive Pulmonary Disease with Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration
Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The... |
|
|
US20150094352 |
METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam,... |
|
|
US20140364479 |
PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE
The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications. |
|
|
US20140018406 |
Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration
Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The... |
|
|
US20130029919 |
TWO PART FORMULATION SYSTEM FOR OPTHALMIC DELIVERY
Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle... |
|
|
US20120214859 |
METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular, it relates to the use of inhibitors of synaptic... |
|
|
US20120136011 |
COMPOUNDS AND METHODS FOR SKIN REPAIR
The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as... |
|
|
US20110306650 |
PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE
The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications. |
|
|
US20100166889 |
METHOD OF TREATING DEPRESSIVE DISORDERS
The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs,... |
|
|
US20150224194 |
Compositions of Glycopyrronium Salt for Inhalation
A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an... |
|
|
US20150065497 |
MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including... |
|
|
US20110159049 |
PHARMACEUTICAL COMPOSITION
The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a... |
|
|
US20060079539 |
Synergistic combination
The invention relates to the combined administration of PDE inhibitors and β2 adrenoceptor agonists for the treatment of respiratory disorders. |
|
|
US20050187205 |
Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
A use of (S)-(−)-α-ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment of particular diseases and new pharmaceutical compositions comprising... |
|
|
US20160151322 |
METALLO-B-LACTAMASE INHIBITORS
A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid... |
|
|
US20150099765 |
Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating
Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further... |
|
|
US20120202773 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT
A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4... |
|
|
US20120148689 |
FILM COMPRISING ACTIVE DRUGS
The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of active drugs through the... |
|
|
US20110028476 |
PROTON PUMP INHIBITORS
A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain,... |
|
|
US20080063719 |
Pharmaceutical Compositions
The present invention relates to pharmaceutical compositions comprising the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the present invention... |
|
|
US20080014271 |
NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING LEVETIRACETAM
The present invention relates to pharmaceutical compositions comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation. |
|
|
US20060205806 |
Synergistic combination
The invention relates to the combined administration of PDE inhibitors and β2 adrenoceptor agonists for the treatment of respiratory disorders. |
|
|
US20150259283 |
FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS
Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft... |
|
|
US20120142684 |
COMPOUNDS AND METHODS FOR SKIN REPAIR
The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as... |